Incyte Aktie News

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for Adults with Relapsed or Refractory DLBCL.

FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in FOP.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2026--New Positive Data Showed INCA033989 Achieved Rapid, Robust & Sustained Clinical & Molecular Responses and Was Well Tolerated in Patients with MF & ET.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2026--Results from Incyte's frontMIND Trial of Tafasitamab (Monjuvi/Minjuvi) Combination at the 2026 EHA Plenary Showed Prolonged Progression Free Survival.

Biotech stock Incyte is working its way up toward a pivot at 112.29, extending a two-day winning streak.

Incyte is upgraded to Buy as pipeline progress and improved EPS estimates offset Jakafi concentration risk. frontMIND Phase 3 data for Monjuvi in first-line DLBCL is promising, supporting potential market share gains despite emerging competition. INCY acquired Vega Therapeutics, adding VGA039 to its hematology portfolio.

Incyte has agreed to buy Vega Therapeutics for up to $2 billion in a deal that expands the biopharmaceutical company's hematology portfolio into bleeding disorders.

Incyte said ​on Monday ‌it has agreed ​to ​acquire Vega Therapeutics, ⁠a wholly ​owned ​subsidiary of Star Therapeutics, in ​a ​deal worth up ‌to $2 ⁠billion, expanding its pipeline ​for ​blood ⁠disorder therapies.